title: Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX-deficient patient with an inhibitor.
authors.affiliation: Division of Pediatric Hematology/Oncology, Children's Memorial Hospital, Northwestern University, Chicago, Illinois.
authors.forename: M L
authors.initials: ML
authors.lastname: Schmidt
authors.forename: H E
authors.initials: HE
authors.lastname: Smith
authors.forename: S
authors.initials: S
authors.lastname: Gamerman
authors.forename: D
authors.initials: D
authors.lastname: DiMichele
authors.forename: S
authors.initials: S
authors.lastname: Glazer
authors.forename: J P
authors.initials: JP
authors.lastname: Scott
mesh_terms: D002648:Child; D003161:Compartment Syndromes / Q000628:therapy; D004334:Drug Administration Schedule; D005164:Factor IX / Q000276:immunology; D015942:Factor VIIa / Q000008:administration & dosage / Q000627:therapeutic use*; D002836:Hemophilia B / Q000276:immunology / Q000628:therapy*; D006470:Hemorrhage / Q000628:therapy; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D007074:Immunoglobulin G; D011994:Recombinant Proteins; D005164:Factor IX; D015942:Factor VIIa